Daniel Gibbs

Integrated Plasmonics Corp. operates as a nanotechnology company. The company was founded on February 4, 2011 and is headquartered in San Francisco, CA.

Insight Venture Management LLC (Insight Venture Partners) is a private equity/ venture capital subsidiary of Insight Holdings Group LLC founded in 1995 by Jeffrey L. Horing and Jerry Fred Murdock. The firm is headquartered in New York.

Charles River Ventures, Inc. is a venture capital firm founded in 1970. The firm is headquartered in Cambridge, Massachusetts.

Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC.

KdT Ventures LLC (KdT Ventures) is a venture capital firm founded in 2017 by Andrew Cain McClary. The firm is headquartered in Austin, Texas.

Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC.

Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA.

Dyno Therapeutics, Inc. engages in the development of therapeutics technologies. It develops technologies for safe, efficient and targeted in vivo delivery of new gene therapies and genome editing therapies. The company was founded by Kelsic Eric David and is headquartered in Watertown, MA.

Unlearn.AI, Inc. develops machine learning technology for clinical drug trails. It offers clinical trial design, synthetic control arms, and super-powered subgroup analysis. The company was founded by Aaron Smith, Charles K. Fisher, and Jonathan Walsh in 2017 and is headquartered in San Francisco, CA.

Andes Ag, Inc. manufactures seeds through microbial technology and artificial intelligence. The company was founded by Gonzalo M. Fuenzalida and is headquartered in Emeryville, CA.

Cyberdontics develops automated robotics for dental clinics. The company was founded by Christopher J. Ciriello and is headquartered in San Francisco, CA.

Part of Dimension Inx LLC, Dimension Inx Corp. engages in developing architect of regenerative microenvironments. The company is based in Chicago, IL. The company was founded by Caralynn Nowinski Collens, Adam E. Jakus, Ramille N. Shah. Caralynn Nowinski Collens has been the CEO since incorporation.

Switch Therapeutics, Inc. is an American biotechnology company that aims to treat a range of diseases affecting the central nervous system and systemic indications with significant unmet need. Switch is based in , and was founded by Dee Datta, who has been the CEO since incorporation. The company is pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. The company's novel gene knockdown approach, the Conditionally Activated siRNA (CASI) platform, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and City of Hope.

Transcera, Inc. is a biotech company founded in 2020. The company is based in Jamaica Plain, MA. The company is on a mission to unlock the potential of biologic drugs for people living with chronic disease.

Gameto, Inc. is a biotechnology company based in New York, NY that focuses on developing novel treatment solutions for women's health, starting with infertility. The company's lead program, Fertilo, aims to make IVF and egg freezing shorter, safer, and more accessible through reduced hormonal injections by maturing eggs outside of the body. The company's goal is to improve assisted fertility outcomes, make the medical burden of menopause optional, and redefine female reproductive health by testing and developing drugs for ovarian disease. Gameto is led by CEO Dina Radenkovic, a physician-turned-entrepreneur, and Chairman Martin Varsavsky, a serial entrepreneur and founder of the largest fertility network, Prelude Fertility.

ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018.

ArrePath, Inc. is an anti-infective drug discovery company that focuses on addressing the health challenge of drug-resistant infections. The platform's proof-of-concept has been demonstrated in studies published in Cell by ArrePath's scientific founder, Zemer Gitai, Ph.D., Edwin Grant Conklin Professor of Biology at Princeton University. The company is based in Princeton, NJ, and is funded by the Boehringer Ingelheim Venture Fund, Insight Partners, Innospark Ventures, Viva BioInnovator, Arimed Capital, PTX Capital, and Nor'easter Ventures. The company utilizes a proprietary machine learning-based platform to efficiently identify anti-infective agents with new mechanisms of action at the outset of the discovery process. This is achieved through a deep understanding and analysis of pathogen behavior. The CEO of the company is Lloyd J. Payne.

DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022.

Capacity Bio, Inc. is a biotech company based in an undisclosed location. The American company is focused on developing a first-in-class mitophagy therapeutic platform and an advanced analytical toolkit to characterize mitochondria. The company was founded by Amy Wang, Stan Louie, and Kathy Rodgers, and the CEO is Kenneth Nicholas Horne.

Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz.